FOLFIRI + bevacizumab
FOLFIRI + bevacizumab is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
2 of 2 finished
0.0%
0 ended early
1
trials recruiting
3
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer
Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
Clinical Trials (3)
Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer
Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3